Skip to main content
Biosynex logo

Biosynex — Investor Relations & Filings

Ticker · ALBIO ISIN · FR0011005933 LEI · 969500H4BGE1HBLGP566 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2026-05-25 M&A Activity
Country FR France
Listing PA ALBIO

About Biosynex

https://www.biosynex.com/en/

Biosynex is a company that specializes in the design, manufacture, and distribution of medical diagnostic solutions. Its core product line consists of Rapid Diagnostic Tests (RDTs) for both professional use in clinical settings and for self-testing by the general public. The professional portfolio includes point-of-care (POC) instruments, molecular biology diagnostics (such as PCR tests), and a wide array of immunodiagnostic assays. For the consumer market, Biosynex offers various self-tests and a range of prevention and monitoring devices, including thermometers, blood pressure monitors, and pulse oximeters. The company focuses on providing simple, rapid, and effective tools for screening, diagnosis, and prevention.

Recent filings

Filing Released Lang Actions
BIOSYNEX ANNONCE AVOIR REÇU UNE OFFRE ENGAGEANTE, SOUS RESERVE DE LA RÉALISATION DE CONDITIONS SUSPENSIVES, POUR LA CESSION DE SON ACTIVITÉ DE BIOLOGIE MOLÉCULAIRE À UN INDUSTRIEL DU SECTEUR
M&A Activity Classification · 88% confidence The document is a press release announcing that Biosynex has received a binding offer to sell its molecular biology business to a third‐party industrial buyer, subject to conditions. It outlines transaction terms, strategic rationale, and next steps. This is a corporate announcement of an M&A transaction, not a periodic report, proxy, or certification. It fits the M&A Activity category.
2026-05-25 French
BIOSYNEX ANNONCE AVOIR RECU UNE OFFRE ENGAGEANTE, SOUS RESERVE DE LA REALISATION DE CONDITIONS SUSPENSIVES, POUR LA CESSION DE SON ACTIVITE DE BIOLOGIE MOLECULAIRE A UN INDUSTRIEL DU SECTEUR
M&A Activity Classification · 87% confidence The document is a regulatory press release announcing that Biosynex has received a binding offer to sell (“cession”) its molecular biology business to an industrial buyer. This is a corporate divestiture transaction and falls under M&A activity. It is not an earnings release, director dealing, or simple report announcement but a material asset sale. Therefore it should be classified as M&A Activity (TAR).
2026-05-25 French
BIOSYNEX SA: RESULTATS ANNUELS 2025 - CHIFFRE D’AFFAIRES T1 2026 ET PERSPECTIVES
Earnings Release Classification · 90% confidence The document is a press release dated April 30, 2026, presenting the annual results for the fiscal year 2025 of BIOSYNEX. It includes detailed financial data such as revenue, margins, operating results, net loss, and financial structure as of December 31, 2025. It also discusses the audit status, including the auditors' opinion with reservations related to asset valuation and going concern uncertainty. The document further provides operational and strategic updates, including the opening of a safeguard procedure, governance changes, and first quarter 2026 revenue and outlook. The presence of comprehensive financial data for the full fiscal year 2025, audit commentary, and management discussion indicates this is an Annual Report or equivalent full-year financial results document. Although it is a press release, the length (15,000 characters) and detailed financial content suggest it is the actual annual results report rather than a mere announcement of report publication. Therefore, the most appropriate classification is Earnings Release (ER), as it is an initial announcement of full-year financial results with key highlights and detailed financial tables, but not the full statutory annual report (10-K) itself. The document also includes some governance information but that is secondary to the financial results focus. Confidence is high given the detailed financial data and audit commentary included.
2026-04-30 French
BIOSYNEX SA: RESULTATS ANNUELS 2025 - CHIFFRE DAFFAIRES T1 2026 ET PERSPECTIVES
Annual Report Classification · 95% confidence The document is a detailed financial communication from BIOSYNEX SA dated April 30, 2026, presenting the annual results for 2025, including detailed financial figures such as revenue, margins, operating results, net results, and balance sheet items. It also discusses the first quarter 2026 revenue and future perspectives. The text includes comprehensive financial data, operational performance analysis, restructuring and safeguard procedures, and governance changes. It explicitly states that the Board of Directors approved the 2025 accounts and that the annual financial report will be published on May 6, 2026. The document is not merely an announcement of a report but contains substantive financial data and management commentary. Therefore, it fits the definition of an Annual Report (10-K) or equivalent comprehensive yearly financial report. Given the detailed financial results and analysis for the full fiscal year 2025, this document is best classified as an Annual Report (10-K).
2026-04-30 French
BIOSYNEX SA: DECALAGE DE PUBLICATION DES COMPTES ANNUELS 2025 ET DU RAPPORT FINANCIER ANNUEL 2025
Report Publication Announcement Classification · 85% confidence The document is a short press release announcing the postponement of the publication dates for the company’s annual financial statements and report. It does not contain the actual financial report itself but merely declares when it will be published. This matches the definition of a Report Publication Announcement (RPA).
2026-04-20 French
BIOSYNEX SA: DECALAGE DE PUBLICATION DES COMPTES ANNUELS 2025 ET DU RAPPORT FINANCIER ANNUEL 2025
Report Publication Announcement Classification · 93% confidence The document is a press release announcing the postponement (“décalage de publication”) of the 2025 annual accounts and 2025 annual financial report rather than providing the reports themselves. It specifically deals with the timing and publication schedule of existing reports. Therefore, it is an announcement regarding the release of company reports, matching the definition of a Report Publication Announcement (RPA).
2026-04-20 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.